Commercial and Pipeline Insight: Hepatitis B - Improved antivirals drive rapid market growth

Abstract

Overview

Introduction

There have been several launches of new Hepatitis B antivirals over the past two to three years that have reshaped the commercial landscape in this field. This report analyses the impact of existing and developmental antivirals and vaccines on the market and its long-term potential.